Access
To read this story in full you will need to login or make a payment (see right).
Business
Nature 440, 990-991 (20 April 2006) | doi:10.1038/440990a; Published online 19 April 2006
Open Innovation Challenges
-
Single-cell Analysis Platform
This Challenge is looking for novel approaches to analyzing changes at a single-cell level. This is...
-
Direct Molecular Detection of Proteins and Nucleic Acids
This Challenge is looking for novel approaches to protein and nucleic acid detection. This is an Id...
- More Challenges
- Powered by:
nature jobs
Postdoctoral Fellow - Computational Genomics - Team 78 – Ref: 80464
- Wellcome Trust Sanger Institute
- Hinxton, Cambridgeshire CB10 1, UK
Gastroenterologist
- South Atlanta Medical Clinic, PC (GI Group)
- Atlanta, GA, USA
Handle with care
Abstract
China's drug market is booming, and will soon be the fifth largest in the world. But despite this potential, global companies are being advised to approach the country with caution, as Colin Macilwain reports.
On the face of it, China is a mouth-watering proposition for international drug companies. In the past five years, the value of its pharmaceutical market has doubled to US$13 billion, according to the Boston Consulting Group — and it is set to double again by 2010.
To read this story in full you will need to login or make a payment (see right).
